DORM
Dorman Products, Inc.
DORM has the edge over NIO overall, supported by stronger valuation and lower modeled downside.
NIO
NIO Inc.
NIO offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
DORM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
DORM's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
NIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Stable | |
| Unavailable |
NIO's revenue is currently strong, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
DORM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $132 | — |
| Cheap | 19x | $125 | -5.6% |
| Current | 20x | $132 | — |
| Fair | 23x | $152 | +15% |
| Expensive | 28x | $191 | +45% |
Historical ranges are pointers, not guarantees.
DORM's PE is in its cheap range at 20x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
NIO PE Valuation
NIO has no meaningful PE right now: it lost money over the past year.
DORM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect DORM's earnings to grow and its profitability to improve, with its revenue holding steady.
NIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
NIO has the edge over DORM on the outlook, with more favorable revenue expectations.
DORM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.63 | +28% |
| Q3 2026 | $6.72 | -16% |
| Q2 2026 | $7.22 | -1.6% |
| Q1 2026 | $6.20 | -11% |
| Q4 2025 | $6.64 | +8.1% |
| Q3 2025 | $8.02 | +34% |
| Q2 2025 | $7.34 | +34% |
| Q1 2025 | $6.96 | +40% |
| Q4 2024 | $6.14 | +50% |
DORM has the edge over NIO on earnings quality, reporting a profit while its opponent remains loss making.
NIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.29 | +$1.45 |
| Q1 2026 | -$0.60 | +$1.16 |
| Q4 2025 | -$1.06 | +$0.60 |
| Q3 2025 | -$1.59 | +$0.02 |
| Q2 2025 | -$1.74 | -$0.10 |
| Q1 2025 | -$1.76 | +$0.06 |
| Q4 2024 | -$1.66 | +$0.21 |
| Q3 2024 | -$1.61 | +$0.32 |
NIO is still losing money, but far less than before: $0.29 per share over the past year, against $1.93 at its worst in late 2023.
DORM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $561.7M | +3.3% |
| Q2 2026 | $544.6M | +0.7% |
| Q1 2026 | $528.8M | +4.2% |
| Q4 2025 | $537.9M | +0.8% |
| Q3 2025 | $543.7M | +7.9% |
| Q2 2025 | $541M | +7.6% |
| Q1 2025 | $507.7M | +8.3% |
| Q4 2024 | $533.8M | +8% |
DORM's revenue has grown year over year for 11 quarters in a row: $562M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -4.7 points |
| Q2 2026 | 21% | +6.1 points |
| Q1 2026 | 11% | -4.7 points |
| Q4 2025 | 5.8% | -10 points |
| Q3 2025 | 19% | +3.7 points |
| Q2 2025 | 15% | +0.8 points |
| Q1 2025 | 16% | +4.2 points |
| Q4 2024 | 16% | +0.6 points |
DORM has the edge over NIO on profitability, with a higher operating margin.
NIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8B | +69% |
| Q1 2026 | $3.8B | +112% |
| Q4 2025 | $5.2B | +76% |
| Q3 2025 | $3.3B | +17% |
| Q2 2025 | $2.9B | +9% |
| Q1 2025 | $1.8B | +21% |
| Q4 2024 | $3B | +15% |
| Q3 2024 | $2.8B | -2.1% |
NIO's revenue has grown year over year for seven quarters in a row: $4.8B last quarter, up 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2.1% | +24 points |
| Q1 2026 | -1.2% | +52 points |
| Q4 2025 | 2.3% | +33 points |
| Q3 2025 | -16% | +12 points |
| Q2 2025 | -26% | +4 points |
| Q1 2025 | -53% | +1.1 points |
| Q4 2024 | -31% | +8.1 points |
| Q3 2024 | -28% | -2.6 points |
NIO's operating margin was −2.1% last quarter, up 24 points from the same quarter a year ago.
DORM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $56.9M | +3022% |
| Q2 2026 | $143.5M | +146376% |
| Q1 2026 | $35.3M | -12% |
| Q4 2025 | $33.5M | -47% |
| Q3 2025 | $1.8M | -95% |
| Q2 2025 | $98K | -100% |
| Q1 2025 | $40.3M | -2.4% |
| Q4 2024 | $63.2M | +30% |
DORM generated $269M in free cash flow over the past year, up 155% from the year before.
NIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$2.1B |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | +$391.3M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | -$2.1B | +$73.9M |
| Q1 2025 | $0 | $0 |
| Q4 2024 | -$391.3M | -386% |
| Q2 2024 | -$2.2B | +$337.9M |
NIO has the edge over DORM on cash flow, with more consistent year-over-year improvement.
DORM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.8x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.2x | Healthy |
DORM's net debt is less than a year of its operating earnings (EBITDA).
NIO Net Leverage
NIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DORM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.7 | Neutral |
| Stochastic | 49.5 | Neutral |
DORM's weekly RSI is 54 (neutral) and its Stochastic is 50 (neutral).
NIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 6.9 | Oversold |
NIO's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
DORM PE vs Consumer Cyclical Sector
| Metric | DORM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 18x | 9% above |
| PE % | 24 | 47 | 23 pts below |
DORM is trading at 20x earnings, in line with the Consumer Cyclical sector's median of 18x.
NIO PE vs Consumer Cyclical Sector
NIO has no meaningful PE right now: it lost money over the past year.
DORM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $127.7 | 3.4% above |
| 20 week MA | $131.3 | 0.5% above |
| 50 week MA | $124.6 | 5.9% above |
| 100 week MA | $128.6 | 2.7% above |
| 200 week MA | $110.3 | 20% above |
DORM has the edge over NIO on trend strength, trading above more of its moving averages.
NIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 9.2% below |
| 20 week MA | $4.01 | 24% below |
| 50 week MA | $4.81 | 37% below |
| 100 week MA | $4.85 | 37% below |
| 200 week MA | $6.03 | 49% below |
NIO is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
DORM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $75.1 | $89.6 | +19% |
| 2021 | $89.6 | $106.4 | +19% |
| 2022 | $106.4 | $81.3 | -24% |
| 2023 | $81.3 | $83.4 | +2.6% |
| 2024 | $83.4 | $132.2 | +58% |
| 2025 | $132.2 | $126.6 | -4.2% |
| 2026 YTD | $126.6 | $132.0 | +4.2% |
DORM has the edge over NIO on returns for 2026, with the stronger performance.
NIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.42 | $45.8 | +1791% |
| 2021 | $45.8 | $30.5 | -33% |
| 2022 | $30.5 | $11.0 | -64% |
| 2023 | $11.0 | $9.07 | -17% |
| 2024 | $9.07 | $4.48 | -51% |
| 2025 | $4.48 | $5.10 | +14% |
| 2026 YTD | $5.10 | $3.05 | -40% |
NIO's yearly returns have swung widely, from +1791% in 2020 to −64% in 2022. It's down 40% so far in 2026.